Global approved new drugs in 2021: retrospect and prospectDU Yi-hang, SUN You-song, CHEN Qian, YANG Zhen-zheng, ZHENG Xiao-nan1033-1041
A new drug in the treatment of gastrointestinal stromal tumor:tyrosine kinase inhibitor avapritinibLI Hong-dou, WANG Long1048-1051
General considerations on the risk assessment of adventitious agents of advanced therapeutic productsXU Long-chang, CUI Jing, WEI Wei1052-1056
The antihypertensive effect of compound reserpine and triamterene tablets on the regulation of intestinal flora in ratJIANG Yu, LIU Shan, YUAN Tian-yi, ZHANG Wen, LI Li, WANG Shou-bao, FANG Lian-hua, DU Guan-hua1057-1065
Research progress of in vitro permeability research of generic drugsLIU Xue-jing, LI Wen-long, GUAN Hao-yue, XU Ming-di1066-1071
Research progress of antitumor small molecule modulators targeting SOS1FAN Yi-qing, TANG Chun-lei, FAN Wei-zheng1072-1079
Retrospective comparison of efficacy and adverse reactions of rituximab and its biosimilar in CHOP chemotherapyHE Xin, ZHUANG Li-ping, LI Qi-zha, HUANG Hong-bing, LIU Tao, ZHOU Jie1080-1084
Practice path and management strategy on accelerating ethical review efficiency in one infectious disease hospitalZHOU Yun-ao, WAN Gang, YANG Zhi-yun, JIA Wang-yan1085-1090
Construction of the evaluation index system for the comprehensive ability of medical ethics committeeWU Jue, DU Xu, LIU Jing, JIANG Hui, TANG Hong-chuan, SUN Yun1091-1095